Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Summit Therapeutics Inc.Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in ChinaMIAMI, August 25, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive topline results from the randomized Phase III HARMONi-GI1 study (AK112-309) evaluating ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC).
- The Rosen Law Firm PAROSEN, GLOBAL INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPRWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.SO WHAT: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
- University of Miami's Gift of 1994 Ibogaine IND to HHS Sets a Standard for Open ScienceThe Multidisciplinary Association for Psychedelic Studies (MAPS) has welcomed the announcement that the University of Miami has gifted the federal government its 1994 ibogaine Investigational New Drug (IND) application.
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 45,984 restricted stock units of the company’s common stock to 23 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of August 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
- Contineum Therapeutics, Inc.Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare ConferenceSAN DIEGO, August 25, 2026--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that management is scheduled to present at the 2026 Morgan Stanley Global Healthcare Conference on Tuesday, September 15th at 5:35 p.m. ET.
- Moody Capital SolutionsAmerican Gene Technologies to Present at The Moody Capital Solutions 2026 Disruptive Growth & Life Sciences ConferenceAmerican Gene Technologies, is a clinical-stage biotechnology company developing AGT103-T, a one-time gene-modified T-cell therapy that is the only program to demonstrate elimination of the HIV viral reservoir in humans., is pleased to announce its participation at the upcoming Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9–10, 2026, in New York City. Drew Palin MD President AGT, will...
- Kaplan Fox & Kilsheimer LLPKaplan Fox Alerts Investors of a Securities Class Action Against Capricor Therapeutics, Inc. (CAPR) - Deadline is September 28, 2026Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Capricor and have suffered losses, you may CLICK HERE to contact us. You may also...
- Sionna Therapeutics, Inc. (SION) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationLaw Offices of Howard G. Smith continues its investigation on behalf of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION) investors concerning the Company’s possible violations of federal securities laws.
- Regeneron entscheidet sich für Veeva Vault CRMCompanies: Regeneron PharmaceuticalsVeeva SystemsFührendes Biopharma-Unternehmen entscheidet sich für agentic CRM im Bereich Life Sciences zur Generierung von Commercial Evidence PLEASANTON, Kalifornien, 25. August 2026 -- Veeva Systems (NYSE: VEEV) gab heute bekannt, dass sich Regeneron Pharmaceuticals weltweit für Veeva...
- Neurologists Interested in Cell Therapy in Neuro-Immune Diseases, but Safety and Logistics Will Shape Adoption, According to Spherix Global InsightsNew research finds neurologists anticipate meaningful durable remission in neuro-immune disease, while long-term safety, patient selection, and treatment logistics remain central to future uptake.
- BeOne Medicines Ltd.BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEASAN CARLOS, Calif., August 25, 2026--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic HER2-positive (HER2+) gastric, gastroesophageal junction,
- U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal AdenocarcinomaZymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its partner, Jazz Pharmaceuticals, has received U.S. Food and Drug Administration (FDA) approval for two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA): Ziihera plus Tevimbra® (tislelizumab-jsgr) and fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+ and IHC 2+/ISH+), and Ziihera plus fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+).